NORTHERN TRUST CORP - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 129 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 1.8%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$10,013,329
+7.1%
1,308,932
+4.5%
0.00%0.0%
Q2 2023$9,352,343
+21.3%
1,251,987
+8.3%
0.00%0.0%
Q1 2023$7,709,032
-13.8%
1,155,777
-0.3%
0.00%0.0%
Q4 2022$8,941,310
-25.9%
1,159,703
+2.3%
0.00%
-33.3%
Q3 2022$12,063,000
+51.0%
1,133,698
+15.5%
0.00%
+50.0%
Q2 2022$7,988,000
+29.8%
981,282
+14.2%
0.00%
+100.0%
Q1 2022$6,154,000
-59.5%
859,544
-3.0%
0.00%
-50.0%
Q4 2021$15,177,000
+163.1%
885,961
+253.4%
0.00%
+100.0%
Q3 2021$5,768,000
-34.8%
250,671
+3.4%
0.00%
-50.0%
Q2 2021$8,846,000242,3760.00%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Obvious Management Services, L.L.C. 3,985,087$42,401,000100.00%
Two Sigma Ventures, LP 903,400$9,612,000100.00%
DCVC Opportunity Fund II GP, LLC 3,951,141$42,040,00054.37%
Data Collective IV GP, LLC 5,941,120$63,214,00049.97%
MIC Capital Management UK LLP 8,451,758$89,927,00016.21%
MV Management XI, L.L.C. 1,971,908$20,981,00015.20%
ArchPoint Investors 1,116,126$11,876,0004.85%
HARVARD MANAGEMENT CO INC 1,509,254$16,058,0002.00%
PLATINUM INVESTMENT MANAGEMENT LTD 2,251,971$23,961,0001.00%
Duquesne Family Office 1,385,950$14,747,0000.84%
View complete list of RECURSION PHARMACEUTICALS IN shareholders